Does Mounjaro Make You Anxious? Evidence and Management

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management in adults with obesity or overweight with comorbidities. Whilst clinical trials have not established a direct causal link between Mounjaro and anxiety, some patients report mood changes during treatment. These may relate to gastrointestinal side effects, metabolic shifts, hypoglycaemia, or pre-existing mental health vulnerabilities rather than a direct pharmacological effect. Understanding the potential indirect mechanisms and knowing when to seek medical advice can help patients manage their treatment safely and effectively.

What Is Mounjaro and How Does It Work?

Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes and, more recently, for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, when used alongside a reduced-calorie diet and increased physical activity. It belongs to a novel class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This dual mechanism distinguishes Mounjaro from other GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or liraglutide (Victoza, Saxenda).

The drug works by mimicking two naturally occurring incretin hormones that are released after eating. GLP-1 stimulates insulin secretion when blood glucose levels are elevated, suppresses glucagon release (which reduces glucose production by the liver), slows gastric emptying, and promotes satiety. GIP also enhances insulin secretion and may influence fat metabolism and energy balance. Together, these actions help to lower blood sugar levels, reduce appetite, and support weight loss.

Mounjaro is administered as a once-weekly subcutaneous injection, starting at a low dose (2.5 mg) for 4 weeks, then increasing in 2.5 mg increments at intervals of at least 4 weeks to a maximum of 15 mg weekly as tolerated. This gradual titration helps minimise gastrointestinal side effects. Clinical trials have demonstrated significant improvements in glycaemic control and substantial weight reduction, leading to its approval by the Medicines and Healthcare products Regulatory Agency (MHRA) and recommendation by the National Institute for Health and Care Excellence (NICE) for specific patient populations, though NHS eligibility criteria may be narrower than the full marketing authorisation.

While Mounjaro is generally well tolerated, like all medications it can cause side effects. The most commonly reported adverse effects are gastrointestinal, including nausea, vomiting, diarrhoea, and constipation. However, some patients have raised concerns about potential mood changes, including feelings of anxiety, prompting questions about whether Mounjaro directly causes or exacerbates anxiety symptoms.

Mounjaro®

Average 22.5% body weight loss

Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.

Start Here

Wegovy®

Average 16.9% body weight loss

Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.

Start Here

Find out if you’re eligible

Why Some People Experience Anxiety on Mounjaro

The relationship between Mounjaro and anxiety is not straightforward, and there is currently no established causal link between tirzepatide and anxiety disorders in clinical trial data or regulatory documentation. Anxiety was not identified as a common adverse effect in the pivotal SURPASS trials for diabetes or the SURMOUNT trials for weight management. The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has also not established a causal association between GLP-1 receptor agonists and significant mood disorders to date. However, individual patient reports and pharmacovigilance signals suggest that some people do experience heightened anxiety or mood changes whilst taking the medication.

Several indirect mechanisms may explain why some individuals feel more anxious on Mounjaro:

• Gastrointestinal distress: Nausea, vomiting, and abdominal discomfort are common, particularly during dose escalation. Persistent physical discomfort can trigger or worsen anxiety, especially in individuals prone to health-related worry or those with pre-existing anxiety disorders.

• Rapid weight loss and metabolic changes: Significant weight reduction can alter body image, energy levels, and potentially affect physiological processes. For some, these changes may be psychologically challenging, particularly if weight loss is faster than anticipated or accompanied by fatigue.

• Hypoglycaemia: Although uncommon with tirzepatide monotherapy, low blood sugar can cause symptoms that mimic anxiety—tremor, sweating, palpitations, and nervousness. Patients taking Mounjaro alongside insulin or sulphonylureas are at higher risk, and dose adjustments of these medications may be necessary.

• Changes in appetite and eating patterns: Reduced hunger and early satiety can disrupt established eating routines and social eating, which may contribute to psychological distress in some individuals.

• Pre-existing mental health conditions: Patients with a history of anxiety, depression, or eating disorders may be more vulnerable to mood changes during any significant medical or lifestyle intervention.

It is also important to consider that anxiety may be coincidental rather than causally related to Mounjaro. Many people starting this medication are managing chronic conditions such as diabetes or obesity, both of which are independently associated with higher rates of anxiety and depression.

Managing Anxiety While Taking Mounjaro

If you are experiencing anxiety whilst taking Mounjaro, there are several practical strategies that may help, alongside ongoing communication with your healthcare team.

Optimise dose escalation: Mounjaro is designed to be started at a low dose (2.5 mg) and increased gradually at intervals of at least 4 weeks. If you are experiencing significant side effects, including anxiety or gastrointestinal symptoms, discuss with your GP or diabetes specialist whether slowing the dose escalation or remaining at a lower maintenance dose might be appropriate. Any dose changes should be clinician-directed and follow the recommended titration schedule. Tolerability often improves over time as the body adjusts.

Monitor blood glucose levels: If you are taking Mounjaro for diabetes, regular blood glucose monitoring can help identify hypoglycaemia, which may present with anxiety-like symptoms. Ensure you understand the signs of low blood sugar and have a management plan in place, including access to fast-acting carbohydrates (15-20g glucose or sugary drink) to treat hypoglycaemia promptly.

Address gastrointestinal symptoms: Nausea and discomfort can exacerbate anxiety. Eating smaller, more frequent meals, avoiding high-fat or spicy foods, and staying well hydrated may reduce gastrointestinal side effects. Consult your healthcare provider before using anti-emetic medications, as selection should consider potential interactions and your medical history.

Maintain psychological support: If you have a history of anxiety or are finding mood changes difficult to manage, consider accessing psychological support. Cognitive behavioural therapy (CBT), mindfulness-based interventions, and counselling can be effective. Your GP can refer you to NHS Talking Therapies (formerly IAPT services), or in many areas, you can self-refer directly to these services.

Lifestyle and self-care: Regular physical activity, adequate sleep, and stress-reduction techniques such as breathing exercises or meditation can support mental wellbeing. Limiting caffeine and alcohol may also help if these substances worsen anxiety symptoms. Peer support groups, either in person or online, may provide reassurance and practical advice from others taking Mounjaro.

Keep a symptom diary: Recording your symptoms, mood, and any triggers can help you and your healthcare team identify patterns and make informed decisions about your treatment plan.

When to Speak to Your GP About Mounjaro Side Effects

It is important to maintain open communication with your GP or diabetes specialist throughout your treatment with Mounjaro. You should contact your healthcare provider if:

• Anxiety is persistent or worsening: If feelings of anxiety are interfering with your daily life, work, relationships, or sleep, do not wait—seek advice promptly. Your GP can assess whether the anxiety is related to Mounjaro, another medical condition, or requires separate treatment.

• You experience severe gastrointestinal symptoms: Persistent vomiting, severe abdominal pain (particularly if radiating to the back), or signs of dehydration (dark urine, dizziness, reduced urination) require urgent medical attention. If pancreatitis is suspected, stop taking Mounjaro and seek immediate medical assessment. These symptoms may indicate pancreatitis or other serious complications, which, although rare, are recognised risks with GLP-1 receptor agonists.

• You have gallbladder symptoms: Right upper abdominal pain, fever, or yellowing of the skin or eyes (jaundice) could indicate gallbladder disease, which is associated with rapid weight loss and GLP-1 receptor agonists. Seek prompt medical advice if these occur.

• You have symptoms of hypoglycaemia: Shakiness, sweating, confusion, palpitations, or irritability—especially if you are taking insulin or sulphonylureas—should be discussed with your healthcare team. Dose adjustments of these medications may be necessary.

• You notice mood changes or depression: Any significant change in mood, including low mood, loss of interest in activities, or thoughts of self-harm, should be reported immediately. Mental health is as important as physical health, and support is available.

• You experience signs of an allergic reaction: Swelling of the face, lips, tongue or throat, breathing difficulties, or severe rash require emergency medical attention. Call 999 or go to A&E immediately if these occur.

• You are considering stopping Mounjaro: Do not stop taking your medication without consulting your GP. There may be alternative strategies to manage side effects, or your healthcare team may recommend a different treatment option that better suits your needs.

For urgent concerns when you cannot reach your GP, contact NHS 111 for advice. For emergencies such as severe allergic reactions, suspected pancreatitis with severe pain, or serious mental health crises, call 999 or go to A&E.

Both patients and healthcare professionals can report suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app), which monitors the safety of medicines in the UK. This helps regulatory authorities identify emerging safety signals and improve patient care.

In summary, while there is no official evidence that Mounjaro directly causes anxiety, some individuals may experience mood changes due to indirect factors such as gastrointestinal distress, metabolic shifts, or pre-existing vulnerabilities. With appropriate monitoring, dose optimisation, and psychological support, most people can manage these symptoms effectively. Always consult your healthcare team if you have concerns about your treatment.

Frequently Asked Questions